Phathom Pharmaceuticals (PHAT) Common Equity: 2022-2025
Historic Common Equity for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Sep 2025 value amounting to -$422.5 million.
- Phathom Pharmaceuticals' Common Equity fell 125.82% to -$422.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$422.5 million, marking a year-over-year decrease of 125.82%. This contributed to the annual value of -$253.6 million for FY2024, which is 248.52% down from last year.
- Per Phathom Pharmaceuticals' latest filing, its Common Equity stood at -$422.5 million for Q3 2025, which was down 4.11% from -$405.8 million recorded in Q2 2025.
- Phathom Pharmaceuticals' 5-year Common Equity high stood at $38.0 million for Q1 2022, and its period low was -$422.5 million during Q3 2025.
- Its 3-year average for Common Equity is -$195.7 million, with a median of -$187.1 million in 2024.
- In the last 5 years, Phathom Pharmaceuticals' Common Equity soared by 351.43% in 2023 and then plummeted by 1,428.57% in 2024.
- Quarterly analysis of 4 years shows Phathom Pharmaceuticals' Common Equity stood at -$74.8 million in 2022, then grew by 2.75% to -$72.8 million in 2023, then slumped by 248.52% to -$253.6 million in 2024, then slumped by 125.82% to -$422.5 million in 2025.
- Its Common Equity stands at -$422.5 million for Q3 2025, versus -$405.8 million for Q2 2025 and -$338.4 million for Q1 2025.